Bleomycin sulfate(cas 9041-93-4) is a water soluble anticancer chemotherapeutic agent commonly used to treat Hodgkin’s lymphoma. Bleomycin comprises a mixture of two components: bleomycin A2 and bleomycin B2. The approximate composition of A2:B2 is 2:1; however, the ratio can vary greatly depending on the lot tested. Bleomycin acts as an anticancer agent by causing single stranded breaks in DNA. The exact mechanism is not well defined however; it is thought to chelate metallic ions to decrease enzyme activity and stability. This effect is believed to cause enzymes to react with oxygen producing free radicals which create single stranded breaks in deoxyribose sugar.
1. J Foot Surg. 1989 Mar-Apr;28(2):141-4.
A perspective study using bleomycin sulfate in the treatment of plantar verrucae.
Sollitto RJ(1), Napoli RC, Gazivoda PL, Hart TJ.
(1)Department of Podiatric Surgery, Kennedy Memorial Hospitals at Saddle Brook,
The authors present a perspective study using bleomycin sulfate in the treatment
of plantar verrucae. Also, they review the literature concerning this modality.
Although the effective cure rate obtained in this study was less than that
reported previously, the authors found bleomycin to be particularly effective in
the treatment of mosaic verrucae.
2. J Dermatol Surg Oncol. 1985 Oct;11(10):972-3.
Bleomycin sulfate--postoperative intralesional usage for giant condylomata.
Buecker JW, Heaton CL.
A patient with giant condyloma of the glans penis was successfully treated with
conservative surgical excision. Postoperatively, intralesional bleomycin sulfate
was utilized in an attempt to prevent tumor recurrence. Follow-up to 2 years has
been unremarkable for clinical regrowth.
3. Oncology. 1984;41(2):114-9.
Carcinogenicity of bleomycin sulfate and peplomycin sulfate after repeated
subcutaneous application to rats.
Habs M, Schmähl D.
Bleomycins (BLM) are widely used as antineoplastic agents either alone or in
combination regimens. Results of earlier studies in experimental animals were
said to be inadequate to evaluate the carcinogenicity of BLM, which is a known
mutagen. In a dose-response study, BLM and peplomycin (PEP) were investigated in
Sprague-Dawley rats of both sexes. For the first 10 weeks weekly doses of 0.35,
0.70, 1.40, and 2.80 mg/kg BLM and of 0.32, 0.63, 1.25, 2.50, and 5.0 mg/kg PEP
were applied subcutaneously (BLM: 30 male and 30 female rats/group; PEP: 25 male
and 25 female rats/group). In the case of BLM, thereafter the doses were given
once every fortnight either for 1 year (BLM: 1.40 and 2.80) or for life (lower
doses). In the case of PEP, application of the high doses was stopped after the
13th time (5.0: 10 X 1/week and 3 X 1 every 2 weeks) and the 19th application
(2.5 mg: 10 X 1/week and 9 X 1/every 2 weeks). After the 10th dosing, the
remaining groups were treated once every fortnight for life. 60 male and 60
female rats served as solvent-treated (physiological saline) controls. The
animals were observed for life. Repeated doses of BLM and PEP reduced body weight
and life expectancy of the animals in a dose-related pattern. Tubular cell
damages and cell proliferations were seen as a symptom of major toxicity in the
kidneys. In this model BLM and PEP are carcinogenic: treatments resulted in
significant dose-related incidences of animals with tumors at the site of
application (fibrosarcomas) and with renal tumors (adenomas, adenocarcinomas,